Rigel Pharmaceuticals Inc (RIGL)
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
There are no comments here yet...